目的 觀察注射用丹參多酚酸聯(lián)合甲磺酸倍他司汀片治療后循環(huán)缺血性眩暈病人的臨床療效。方法 將96例患者隨機(jī)分為2組，各48例，對(duì)照組采取常規(guī)治療，口服甲磺酸倍他司汀片，6 mg/次，3次/d，觀察組加用注射用丹參多酚酸治療，0.13 g加入到0.9%氯化鈉注射液250 mL中靜滴，1次/d，14 d后比較兩組椎基底動(dòng)脈供血和血流變指標(biāo)、臨床療效和不良反應(yīng)。結(jié)果 觀察組治療后椎基底動(dòng)脈血流速度（收縮期峰流速、舒張期末流速、平均流速）和血流變學(xué)指標(biāo)（全血比黏度、血漿比黏度、纖維蛋白原）改善情況明顯優(yōu)于治療前，且治療后觀察組優(yōu)于對(duì)照組的，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；觀察組痊愈率和總有效率均明顯高于對(duì)照組，差異具有統(tǒng)計(jì)學(xué)意義（P<0.05），且兩組均無不良反應(yīng)發(fā)生。結(jié)論 注射用丹參多酚酸聯(lián)合甲磺酸倍他司汀片治療椎后循環(huán)缺血性眩暈具良好的療效，值得臨床推廣應(yīng)用。

Objective To observe the clinical effect of Salvianolic Acids for Injection (SAFI) combined with Betahistine Mesilate Tablets (BMT) in the treatment of posterior circulation ischemic vertigo (PCIV). Methods In the 96 cases, patients with PCIV were randomly divided into observation group (n=48) and control group (n=48). Patients in the control group were given conventional therapy and oral BMT 6 mg tid, while the observation groups were treated by BMT combined with 0.13 g SAFI added for 250 mL 0.9% sodium chloride intravenous drip qd. After all patients in the two groups treated for 14 d, the blood flow velocity of vertebrobasilar artery, hemorheological indexes, clinical efficacy, and adverse reactions of two groups were compared. Results After treatment, the blood flow velocity of vertebrobasilar artery (Vs, Vd, Vm), and hemorheological indexes (whole blood viscosity, plasma viscosity, fibrinogen) in the observation groups were significantly improved than those before treatment, the observation groups was significantly improved than control groups, and the difference was statistically significant (P<0.05). The recovery rate and total efficiency of the observation groups were significantly higher than the control groups (P<0.05), and there were no ADR patients in both groups. Conclusions SAFI combined with BMT in the treatment of PCIV has a good effect and is worthy of clinical application.

河南省中醫(yī)藥科學(xué)研究專項(xiàng)課題（2014ZY02059）；鄭紹周全國(guó)名老中醫(yī)藥專家傳承工作室建設(shè)項(xiàng)目（國(guó)中醫(yī)藥人教函[2012]149號(hào)）